Skyhawk Therapeutics
@skyhawktx.com
Skyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate critical RNA targets and revolutionize patient treatment for some of the world's most intractable diseases.
Skyhawk Therapeutics's Company Logos
Skyhawk Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#27AAE1
Curious Blue
39, 170, 225
198, 76, 52
83, 24, 0, 12
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#080808
Cod Gray
8, 8, 8
0, 0, 3
0, 0, 0, 97
About Skyhawk Therapeutics
Skyhawk Therapeutics is a pioneering brand that is dedicated to revolutionizing disease treatment. They specialize in developing small molecule therapeutics that correct RNA expression, aiming to provide innovative solutions for various health conditions. Led by CEO and Chairman Bill Haney, who has a strong background in entrepreneurship and environmental advisory, as well as Chief Scientific Officer Kathleen McCarthy, who has contributed to the development of treatments for Spinal Muscular Atrophy (SMA), Skyhawk Therapeutics is committed to advancing scientific research and improving patient outcomes.
With a distinguished Scientific Advisory Board, including experts like Prof. Tyler Jacks, Prof. Frédéric Allain, Prof.
Steven Bell, Prof. Ben Blencowe, Dr. Ben Ebert, and Dr.
Rob Hershberg, the brand brings together a wealth of knowledge and expertise in areas such as cancer research, RNA biology, and medical oncology. Skyhawk Therapeutics is at the forefront of innovation and their dedication to developing effective therapeutics makes them a trusted force in the industry
Company type
Privately Held
Year founded
2016
Company size
51-200 employees
